

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 17th January 2024 10-12:30

Microsoft Teams Meeting

Present:	Mehrdad Malekian Victoria Gemmell Moira Spence (item 8a only) Tyra Smyth Stephanie Dundas (until 8c) Gail Richardson Kelly Baillie (item 12 only)	David Semple Linda Johnstone Christine Gilmour Zhuo Min Chong (item 8d only) Christine Carswell Penny Brankin Mark Kirk
-----------------	---	---

1. Apologies:	Kirsty, Macfarlane, Emma Harris Colin Angus	Alistair Brown
----------------------	---	----------------

2. Declaration of Interest	nil	
-----------------------------------	-----	--

Area Drugs and Therapeutics Committee Meeting Minutes

Item	Notes	Action
3	<u>Minutes/Actions from the last meeting</u> The minutes were accepted as true records and can now be published	VG
4	<u>Matters Arising</u>	
a)	Ogluo Guidance only covers up to age 16. Needs clarity of plan when patients transition to adult services. Eligibility should be 2 or more of the criteria noted Concerns around potentially escalating numbers. Diabetes service could be asked to maintain control of numbers. To be taken to both Prescribing Management Boards for further discussion	
b)	IV Fluids Some small typos to be amended. Clarity required on a point around hypernatremia. Approved pending these changes.	
c)	NHSL HF Guideline-update awaited To remain on agenda	
d)	Orbital Cellulitis Guideline NHSL Feedback from ophthalmology reviewed. Group agreed to change initial aim to “Initial Management of Orbital Cellulitis” To confirm who would manage this patient group. Add doses and units of measurements for medicines. The document is approved pending these changes Final copy to be shared for filing	

<p>e)</p> <p>f)</p> <p>g)</p> <p>i)</p>	<p>Paracetamol to Prevent or Treat Fever post MenB Vaccination Typo on pg 1. Should read “ml” Author title to be changed from Paediatric to Neonatal pharmacist Approved pending these changes</p> <p>Hypokalaemia-Paediatrics Paediatric Treatment Of Hypokalaemia This was approved with no changes</p> <p>Palliative Care Prescribing Record Previous comments made by the committee were discussed with the SLWG. Further clarification was shared and were accepted by the committee. Approved with no changes</p> <p>Items which should not be prescribed in NHSL This has been shared widely and has good support from clinicians and patients. There was discussion around some items which have specific use, particularly in the acute setting. It was agreed that these items were not covered by this guidance and these is no need to change current practice. Some updates may be required to the Joint Adult Formulary. VG to liaise with EH To confirm where this will be held for easy access. This was accepted by the committee.</p>	
<p>5</p>	<p>SMC Advice-CONFIDENTIAL</p> <p>Please all see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website after 10.00 am on Monday 12 February 2024.</p> <p>Full Submissions</p> <ul style="list-style-type: none"> • cabozantinib (Cabometyx) Ipsen Ltd SMC2590 Not Recommended • secukinumab (Cosentyx) Novartis Pharmaceuticals UK Ltd SMC2592 Accepted Restricted with PAS REFER TO DERMATOLGY • dupilumab (Dupixent) Sanofi SMC2598 Accepted with PAS REFER TO DERMATOLGY • Loncastuximab tesirine (Zynlonta) Swedish Orphan Biovitrum Ltd (Sobi) SMC2609 Accepted Restricted with PAS Await advice from WoSCAN • difelikefalin solution for injection (Kapruvia) CSL Vifor SMC2623 Accepted Restricted with PAS REFER TO RENAL <p>Non Submissions</p> <ul style="list-style-type: none"> • ravulizumab (Ultomiris) (gMG) Alexion Pharma UK Ltd SMC2657 • ravulizumab (Ultomiris) (NMOSD) Alexion Pharma UK Ltd SMC2658 <p>FOR INFORMATION <i>Note: Budget Impact templates will be sent to NHS Board contacts and Directors of Pharmacy under separate cover.</i></p> <p>Paediatric Licence Extensions</p> <p>FOR NOTING</p>	

6.	<p><u>SMC follow up</u> This was discussed. There is no further update on the treatment of migraine from Dec meeting as the GGC team are meeting in January to finalise guidelines/pathways. There will be more concrete information once these guidelines are approved.</p>	
7.	<p><u>Lanarkshire Formulary</u> These were accepted</p>	
8.	<p><u>Clinical Protocols</u></p> <p>(a) Sativex-Moira Spence This was discussed. It was noted that GP Sub may have concerns around prescribing while still under review, however the group agreed that the item had merit and was accepted. Sativex is approved for use in NHS for patients under the ongoing care of the MS service and can be added to the formulary.</p> <p>(b) Off-Label Prescribing-Beth Goundry <i>Prescribing for Off-Label Indications or Unlicensed Medicines</i> The group agreed it would be helpful to link with KMAC to ensure alignment with current update to NHS Unlicensed policy. Reference to “Unauthorised medicines” would be better described as “off-label or unlicensed” as the medicines noted are recommended in Scottish Palliative Care Guidelines or Palliative Care Formulary and therefore do not require further authorisation for use. A comment regarding this would be helpful on the document. This was accepted pending these changes</p> <p><i>Prescribing in Palliative Care - Patient Information Leaflet</i> This was accepted with no changes</p> <p>(c) Management of Malignant Hypercalcaemia This is an update of existing guidance. Query around which specialist should be consulted as described on the flowchart on pg 5 Flowchart detail-expand units and add strength for NaCl where used Clarify reference range for elevated calcium levels (green box) Confirm timeframe for recheck of U and E’s post zoledronic acid treatment To return for final review</p> <p>(d) Hip Fracture acute treatment pathway ZMC presented this. Abbreviation Zol to be expanded (zoledronic acid). Question around need for treatment out of hospital. Small possibility that patients may be discharged to off-site bed. The fracture liaison service will follow up these patients after discharge. Accepted by the group</p>	LJ
9.	<p><u>ADTC New Medicines Decisions</u> The was accepted</p>	

10.	<p><u>Unlicensed Medicines</u></p> <p>nil</p>	
11.	<p><u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update</p>	
12.	<p><u>Regional Cancer Advisory Network</u> Proposals for breast cancer prevention treatment are planned for discussion by NCMAG in March/April. Depending on decisions, implementation will need planning. Further discussion will take place once the outcomes are known. These were accepted. WoSCAN vaccination guideline. Development of this was supported by NHSL Clinical guidelines have been updated. Immunotherapy treatment-number of patients increasing. Schedules have been aligned.</p>	
13.	<p><u>Patient Safety Alerts</u></p> <p>GLP-1 Safety Alert Wider discussion on how best to action these. CG will take forward</p>	
14.	<p><u>Lay member related items</u></p> <p>nil</p>	
15.	<p><u>Correspondence</u></p> <p>(a) <u>ADTC Collaborative</u></p> <p>(i) nil</p> <p>(ii) Opioid SBAR-Antony Carson The recommendation was discussed and agreed</p>	
15.	<p><u>Pharmacy & NMAHP Prescribing Governance</u></p> <p>nil</p>	
16.	<p><u>AOCB</u></p> <p>nil</p>	
17.	<p><u>Date of next meeting</u> Wednesday 21st February 2023 10am-12:30pm MS TEAMS</p>	